Open Data

Clene ( CLNN ) Announces New Data Show CNM - Au8 Preserved ALS Patient Function and Slowed Disease Progression in the Open - Label Extension of the Phase 2 RESCUE - ALS Trial

Clene Inc. has announced new results showing preserved ALS patient function score and delayed time to clinical worsening from the most recent 12-month data cut of the open-label extension of a trial in people with early amyotrophic lateral sclerosis (ALS).

Source: streetinsider.com
Published on 2023-03-06

Related news

• RARE - X Study Delivers Insights for Diversity , Equality , and Inclusion Programs
• Using machine learning models to guide the design of long - acting injectable drug formulations
• Scientists use machine learning to fast - track drug formulation development
• Wisconsin getting $400 million from opioid settlement